Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% of ...

As a health journalist, I’m doing my best to keep up with all things weight loss drugs, but with headlines rolling in every ...

An experimental weight-loss pill is showing promising results, helping people drop 13% of their body weight in a three-month period. The results from early clinical trials were presented by Novo ...